Skip to content

13F-HR filed by Flagship Pioneering, LLC

Flagship Pioneering, LLC filed this 13F-HR for the quarter ended 2020-09-30, filed 2020-11-16, with 8 holding rows worth $3,619,952,000.

Accession
0000950123-20-012128
Filed
2020-11-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2020

A holdings report, 17 entries on the cover page, a total value of $3,619,952,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $3,619,952,000 with VALUE read as thousands by filing date, 13F file number 028-17559. The quarter's positions are built on this report. The resolved quarter.

Other managers

  • included managerFlagship Ventures Fund V General Partner LLC 028-18466
  • included managerFlagship Ventures Fund IV General Partner LLC 028-17238
  • included managerNoubar Afeyan 028-19988

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
MODERNA INC60770K107COM30,871,524$2,184,161,000thousands by filing date
SERES THERAPEUTICS INC81750R102COM21,571,764$610,696,000thousands by filing date
KALEIDO BIOSCIENCES INC483347100COM19,360,710$214,323,000thousands by filing date
DENALI THERAPEUTICS INC COM24823R105Stock5,980,263$214,273,000thousands by filing date
RUBIUS THERAPEUTICS INC78116T103COM38,296,526$191,866,000thousands by filing date
EVELO BIOSCIENCES INC299734103COM22,900,069$120,684,000thousands by filing date
AXCELLA HEALTH INC05454B105COM12,548,414$57,973,000thousands by filing date
SYROS PHARMACEUTICALS INC87184Q107COM2,938,494$25,976,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-20-012128this filing2020-11-16acceptance time not in the bulk data set